Study of SCTC21C for people with systemic lupus erythematosus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new investigational drug called SCTC21C for people with moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if the drug can help control lupus symptoms and reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with lupus (SLE) at least 12 weeks before the start of the study.
- Your disease activity score must be 8 or higher on a standard lupus scale.
- You must be on at least one stable lupus medication (like steroids, antimalarials, or immunosuppressants).
- You cannot have severe lupus complications like active kidney disease, nervous system issues, or recent heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This study tests an investigational drug that targets a protein involved in lupus. The goal is to see if it can reduce lupus activity and improve symptoms.
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.